BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18376407)

  • 21. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts.
    Puissant B; Roubinet F; Massip P; Sandres-Saune K; Apoil PA; Abbal M; Pasquier C; Izopet J; Blancher A
    AIDS Res Hum Retroviruses; 2006 Feb; 22(2):153-62. PubMed ID: 16478397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection.
    Mehandru S; Poles MA; Tenner-Racz K; Jean-Pierre P; Manuelli V; Lopez P; Shet A; Low A; Mohri H; Boden D; Racz P; Markowitz M
    PLoS Med; 2006 Dec; 3(12):e484. PubMed ID: 17147468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An additive effect of protective host genetic factors correlates with HIV nonprogression status.
    Salgado M; Simón A; Sanz-Minguela B; Rallón NI; López M; Vicario JL; Benito JM; Rodés B
    J Acquir Immune Defic Syndr; 2011 Apr; 56(4):300-5. PubMed ID: 21084992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients.
    Yeregui E; Viladés C; Domingo P; Ceausu A; Pacheco YM; Veloso S; Inciarte A; Vidal-González J; Peraire M; Perpiñán C; Falcó V; Masip J; Alba V; Vargas M; Martí A; Reverté L; Mallolas J; Vidal F; Peraire J; Rull A
    EBioMedicine; 2020 Dec; 62():103077. PubMed ID: 33166788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Pierdominici M; Giovannetti A; Ensoli F; Mazzetta F; Marziali M; De Cristofaro MR; Santini-Muratori D; Leti W; Aiuti F
    J Acquir Immune Defic Syndr; 2002 Feb; 29(2):122-31. PubMed ID: 11832680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The predictive role of CD4
    Li CX; Li YY; He LP; Kou J; Bai JS; Liu J; Tian B; Cao LJ; Wang KH; Kuang YQ
    BMC Immunol; 2019 Aug; 20(1):31. PubMed ID: 31455209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
    J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCL3L1 and HIV/AIDS susceptibility.
    Urban TJ; Weintrob AC; Fellay J; Colombo S; Shianna KV; Gumbs C; Rotger M; Pelak K; Dang KK; Detels R; Martinson JJ; O'Brien SJ; Letvin NL; McMichael AJ; Haynes BF; Carrington M; Telenti A; Michael NL; Goldstein DB
    Nat Med; 2009 Oct; 15(10):1110-2. PubMed ID: 19812560
    [No Abstract]   [Full Text] [Related]  

  • 30. The impact of CCL3L1 copy number in an HIV-1-infected white population.
    Lee EY; Yue FY; Jones RB; Lo C; Sheth P; Hyrcza MD; Kovacs C; Benko E; Kaul R; Ostrowski M
    AIDS; 2010 Jun; 24(10):1589-91. PubMed ID: 20442635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy.
    Price P; Mathiot N; Krueger R; Stone S; Keane NM; French MA
    J Clin Virol; 2001 Oct; 22(3):279-87. PubMed ID: 11564593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reply to: "Experimental aspects of copy number variant assays at CCL3L1".
    He W; Kulkarni H; Castiblanco J; Shimizu C; Aluyen U; Maldonado R; Carrillo A; Griffin M; Lipsitt A; Beachy L; Shostakovich-Koretskaya L; Mangano A; Sen L; Nibbs RJ; Tiemessen CT; Bolivar H; Bamshad MJ; Clark RA; Burns JC; Dolan MJ; Ahuja SK
    Nat Med; 2009 Oct; 15(10):1117-20. PubMed ID: 19812563
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
    Brumme ZL; Brumme CJ; Chui C; Mo T; Wynhoven B; Woods CK; Henrick BM; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2007 Jun; 195(11):1694-704. PubMed ID: 17471440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of polymorphisms in the HCP5 and HLA-C, and ZNRD1 genes on HIV viral load.
    Thørner LW; Erikstrup C; Harritshøj LH; Larsen MH; Kronborg G; Pedersen C; Larsen CS; Pedersen G; Gerstoft J; Obel N; Ullum H
    Infect Genet Evol; 2016 Jul; 41():185-190. PubMed ID: 27083073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China.
    Li X; Ding H; Geng W; Liu J; Jiang Y; Xu J; Zhang Z; Shang H
    BMC Infect Dis; 2019 May; 19(1):373. PubMed ID: 31046702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
    Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C.
    Grünhage F; Nattermann J; Gressner OA; Wasmuth HE; Hellerbrand C; Sauerbruch T; Spengler U; Lammert F
    J Hepatol; 2010 Feb; 52(2):153-9. PubMed ID: 20044164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy.
    Nicholson JK; Browning SW; Hengel RL; Lew E; Gallagher LE; Rimland D; McDougal JS
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):105-15. PubMed ID: 11404531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental aspects of copy number variant assays at CCL3L1.
    Field SF; Howson JM; Maier LM; Walker S; Walker NM; Smyth DJ; Armour JA; Clayton DG; Todd JA
    Nat Med; 2009 Oct; 15(10):1115-7. PubMed ID: 19812562
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV/AIDS. HIV: experiencing the pressures of modern life.
    Nolan D; James I; Mallal S
    Science; 2005 Mar; 307(5714):1422-4. PubMed ID: 15746416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.